Imv Investor Relations Material
Latest events
Q4 2022
Imv
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Imv Inc
Access all reports
IMV Inc. operates as a clinical-stage immuno-oncology company. Its lead candidate is DPX-Survivac, which is in Phase II trial for the treatment of recurrent ovarian cancer, as well as in Phase I/II trial for the treatment of advanced cancers; and developing a combination therapy regimen with checkpoint inhibitor. The company's product candidates also include DPX-E7, which is in Phase I/II trial for the treatment of human papillomavirus associated cancers; and DIANOVA for the treatment of solid tumors. In addition, it is developing DPX-RSV that has completed preclinical trials for used in lung cancer; and DPX-COPD vaccine to treat chronic obstructive pulmonary disease. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IMV
Country
🇺🇸 United States